Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg ...

Telehealth firm 9amHealth has partnered with billionaire entrepreneur Mark Cuban's Cost Plus Drug Company to offer U.S.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Most importantly, don’t leave nutrition and exercise out of the equation. There is a huge difference between a healthy and an unhealthy thin person.

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Innovent completes first patient dosing in seventh phase 3 trial (GLORY-OSA) of mazdutide in China with moderate-to-severe OSA & obesity: San Francisco, US Tuesday, June 17, 2025, ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.